We test the hypothesis that a SNPs associated with the expression of XBP1 in pancreatic islet cells drives an increased risk of T2DM, reduced beta-cell function (HOMA-B), impaired pre-treatment glycaemic control (HbA1c), and impaired response to insulin secretagogues. The gene discussed is INS; the disease is type 2 diabetes mellitus.